Perioperative tislelizumab plus chemotherapy for locally advanced gastric cancer: A randomized, prospective phase 2 trial
Cancer Cell · 2026
DOI: 10.1016/j.ccell.2026.06.015 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Cell, 2026. Verfasst von Zhiyuan Xu und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Province Natural Science Foundation, Medical Science and Technology Project of Zhejiang Province, National Natural Science Foundation of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China; Key Laboratory of Prevention, Diagnosis and Therapy of Upper…
- Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.
- Department of Gastric Surgery, Liaoning Cancer Hospital, Shenyang, Liaoning, China.
- Department of Gastric Surgery, Sichuan Cancer Hospital, Chengdu, Sichuan, China.
- Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Pathology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.
Förderung
- Zhejiang Province Natural Science Foundation
- Medical Science and Technology Project of Zhejiang Province
- National Natural Science Foundation of China
Zitieren
APA
Xu, Z., Hu, C., Yang, L., Yu, P., Zhang, Y., Chen, J., Zheng, G., Chen, X., Zhang, T., He, W., Meng, X., Yu, P., Du, Y., Liu, X., Liu, Y., Wang, Y., Wu, X., Pan, S., Zhang, R., …, & Cheng, X. (2026). Perioperative tislelizumab plus chemotherapy for locally advanced gastric cancer: A randomized, prospective phase 2 trial. Cancer Cell. https://doi.org/10.1016/j.ccell.2026.06.015
Vancouver
Xu Z, Hu C, Yang L, Yu P, Zhang Y, Chen J, et al. Perioperative tislelizumab plus chemotherapy for locally advanced gastric cancer: A randomized, prospective phase 2 trial. Cancer Cell. 2026. doi:10.1016/j.ccell.2026.06.015
BibTeX
@article{Xu2026,
author = {Xu, Zhiyuan and Hu, Can and Yang, Litao and Yu, Pengfei and Zhang, Yanqiang and Chen, Jiahui and Zheng, Guoliang and Chen, Xiaodong and Zhang, Tao and He, Weiyang and Meng, Xiangyu and Yu, Panpan and Du, Yian and Liu, Xiaowen and Liu, Youdong and Wang, Yongxiang and Wu, Xiaoxiao and Pan, Siwei and Zhang, Ruolan and Zhang, Shengjie and Xiong, Zhirong and Sun, Wei and Dong, Chuanxin and Liu, Jiajun and Wu, Yuexian and Cheng, Xiangdong},
title = {Perioperative tislelizumab plus chemotherapy for locally advanced gastric cancer: A randomized, prospective phase 2 trial},
journal = {Cancer Cell},
year = {2026},
doi = {10.1016/j.ccell.2026.06.015}
}
EUVIMED